Benzimidazole treatment of cystic echinococcosis

El‐On, Joseph

doi:10.1016/s0001-706x(02)00217-6

Cited by 134 publications

(79 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inoperable AE cases must undergo longterm, often life-long, chemotherapy with albendazole (ABZ) and/or mebendazole (MBZ) (Reuter et al 2000(Reuter et al , 2004. Extensive animal experimentation and observations in human patients sufferering from AE have demonstrated that ABZ and MBZ exhibit a parasitostatic rather than a parasitocidal effect (El-On, 2002 ;Reuter et al 2004). Thus, benzimidazoles only prevent E. multilocularis growth, and the recurrence rates after interruption of therapy are high.…”

Section: I M I T a T I O N S O F C U R R E N T C H E M O T H E R A mentioning

confidence: 99%

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

et al. 2007

View full text Add to dashboard Cite

Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of which the metacestode (larval) stages cause the diseases cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. Albendazole and mebendazole are presently used for chemotherapeutical treatment. However, these benzimidazoles do not appear to be parasiticidal in vivo against AE. In addition, failures in drug treatments as well as the occurrence of side-effects have been reported. New drugs are needed to cure AE and CE, which are considered to be neglected diseases. Strategies currently being implemented to identify novel chemotherapeutical treatment options include (i) conventional primary in vitro testing of broad-spectrum anti-infective drugs, either in parallel with, or followed by, animal experimentation ; (ii) studies of drugs which interfere with the proliferation of cancer cells and of Echinococcus metacestodes ; (iii) exploitation of the similarities between the parasite and mammalian signalling machineries, with a special focus on targeting specific signalling receptors ; (iv) in silico approaches, employing the current Echinococcus genomic database information to search for suitable targets for compounds with known modes of action. In the present article, we review the efforts toward obtaining better anti-parasitic compounds which have been undertaken to improve chemotherapeutical treatment of echinococcosis, and summarize the achievements in the field of host-parasite interactions which may also lead to new immuno-therapeutical options.

show abstract

Section: I M I T a T I O N S O F C U R R E N T C H E M O T H E R A mentioning

confidence: 99%

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In addition, medical therapy such as Benzimidazole derivatives given either alone or as a supplementary treatment is currently used in cystic hydatid disease. Owing to the developments in percutaneous treatment, the percutaneous approach has also been reported as a safe and effective alternative treatment (2,(8)(9)(10).…”

mentioning

confidence: 99%

Radiologic findings and percutaneous treatment of a rare giant soft tissue hydatid cyst

Yücesoy

Öztürk

Hekįmoğlu

2013

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

“…Inoperable AE cases must undergo long-term chemotherapy, often life-long, which is based on ABZ and/or MBZ (Reuter et al, 2000(Reuter et al, , 2004. Extensive animal experimentation and observations in human patients sufferering from AE have demonstrated that ABZ and MBZ exhibit a parasitostatic rather than a parasitocidal effect (El-On, 2002;Reuter et al, 2004). Therefore, recurrence rates after interruption of therapy are high.…”

Section: Current Therapiesmentioning

confidence: 99%

Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options

Hemphill

Müller

2009

J. Helminthol.

View full text Add to dashboard Cite

Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of which the metacestode (larval) stages cause the neglected diseases cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. The benzimidazoles albendazole and mebendazole are presently used for the chemotherapeutical treatment, alone or prior to and after surgery. However, in AE these benzimidazoles do not appear to be parasiticidal in vivo. In addition, failures in drug treatments as well as the occurrence of side-effects have been reported, leading to discontinuation of treatment or to progressive disease. Therefore, new drugs are needed to cure AE and CE. Strategies that are currently employed in order to identify novel chemotherapeutical treatment options include in vitro and in vivo testing of broad-spectrum anti-infective drugs or drugs that interfere with unlimited proliferation of cancer cells. The fact that the genome of E. multilocularis has recently been sequenced has opened other avenues, such as the selection of novel drugs that interfere with the parasite signalling machinery, and the application of in silico approaches by employing the Echinococcus genome information to search for suitable targets for compounds of known mode of action.

show abstract

Benzimidazole treatment of cystic echinococcosis

Cited by 134 publications

References 50 publications

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis

Radiologic findings and percutaneous treatment of a rare giant soft tissue hydatid cyst

Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options

Contact Info

Product

Resources

About